Drugs / VRC-HIVMAB060-00-AB
last change Dec 2020 re-read 3 minutes ago

VRC-HIVMAB060-00-AB

also known as VRC01

Monoclonal antibody

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 3

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT02471326 Jul 2015 → Apr 2017 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01993706 Nov 2013 → Feb 2015 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01950325 Aug 2013 → Aug 2015 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Comparator or background therapy1 trial
Phase 1 NCT03831945 Comparator Apr 2019 → Dec 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Terminated No outcome recorded Stop: Enrollment

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as VRC-HIVMAB060-00-AB ClinicalTrials.gov intervention name — accepted as the source's own label NCT03831945 ↗
3

NCT02471326 ↗

NCT01993706 ↗

NCT01950325 ↗

Known as VRC01 “VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing HIV-1 monoclonal antibody (mAb) isolated from the B cells of an HIV-infected patient.” PMID 26332605 ↗ Sep 2015
2

“This is the first clinical trial of the VRC-HIVMAB060-00-AB (VRC01) monoclonal antibody.” NCT01950325 ↗

“VRC-HIVMAB060-00-AB (VRC01)” NCT02471326 ↗

Action Inhibit “In summary, a single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains.” PMID 26702094 ↗ Dec 2015
Modality Monoclonal antibody “VRC01 Human Monoclonal Antibody” NCT01950325 ↗
Route Intravenous “Administered intravenously or subcutaneously to HIV-Infected Adults” NCT01950325 ↗
Route Subcutaneous “Administered intravenously or subcutaneously to HIV-Infected Adults” NCT01950325 ↗